|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.68 - 32.79|
|52 Week Range||26.30 - 34.98|
|Beta (3Y Monthly)||0.50|
|PE Ratio (TTM)||21.35|
|Forward Dividend & Yield||1.07 (3.12%)|
|1y Target Est||35.55|
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
This approval supports Roche`s personalized healthcare strategy to provide treatment to patients who can benefit most from a specific medicine. OTCQX: RHHBY) today announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer.
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Ionis Pharmaceuticals was slammed Wednesday on competitive gene-therapy data from Novartis' AveXis unit and amid apparently disappointing comments from Roche in Huntington's disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...
By John Miller ZURICH (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald ...
Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ...
Roche, the Swiss drugmaker, has raised its full-year sales outlook on strong sales growth for the first three months of 2019. The company said it now expects mid-single digits sales growth for 2019 from low to mid-single digit range as forecast at the end of January. “We have started the year with strong sales growth, driven by the newly launched products in our Pharmaceuticals Division,” said Roche chief executive Severin Schwan.
Basel, 17 April 2019 Group sales increase 8% 1 at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics ...
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Even in what has been a notoriously high-volume sector, March was a particularly strong month for cannabis securities that trade on OTC Markets. Six of the top 10 most active securities in March on the ...
Walmart is stepping into the subscription box space. The retailer is teaming up with Kidbox to deliver curated clothing boxes to its customers, including such brands as Miniville, Material Girl, Jessica Simpson and Chickpea. Yahoo Finance's Dan Roberts, Kristin Myers, and Julia La Roche sat down with Kidbox's CEO Miki Berardelli to discuss the partnership.
Walmart is partnering with Kidbox to launch a subscription delivery box for kids. Yahoo Finance's Julia La Roche and Alexis Christoforous discuss.
JPMorgan Chase posted adjusted earnings per share of $2.65, versus analysts’ forecasts of $2.35 for the first quarter Friday. Yahoo Finance’s Julia La Roche and Alexis Christoforous break down the details.
Jeff Bezos is out with his annual letter to Amazon shareholders, which started with "Third-party sellers are kicking out first party butt.' Yahoo Finance's Seana Smith and Julia La Roche discuss.